Proliferative activity and genetic changes in adrenal cortical tumors examined by flow cytometry, fluorescence in situ hybridization and immunohistochemistry

International Journal of Urology

Volumn 12, Issue 2, 2005, Pages 121-127

  Takehara, Kousuke ^a   Sakai, Hideki ^a   Shono, Takefumi ^a   Irie, Junji ^a   Kanetake, Hiroshi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Adrenal cortical neoplasms; Chromosome 17; DNA ploidy; Ki 67; p53

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; KI 67 ANTIGEN; PARAFFIN; PROTEIN P53;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADULT; AGED; ARTICLE; BENIGN TUMOR; CELL PROLIFERATION; CHROMOSOME 17; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING SYNDROME; DISOMY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; HYPERALDOSTERONISM; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; MALIGNANT NEOPLASTIC DISEASE; NUMERICAL CHROMOSOME ABERRATION; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TETRAPLOIDY; TUMOR VOLUME;

ADENOMA; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; CARCINOMA; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 17; CUSHING SYNDROME; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERALDOSTERONISM; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MALE; MIDDLE AGED; PLOIDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16244421434     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.00999.x     Document Type: Article

References (21)

1. Shono T, Sakai H, Irie J et al. Relationship between flow cytometric DNA ploidy and nuclear grade with endocrine dysfunction in adrenal cortical adenomas. Urology 2000; 56: 337-41.
2. Shono T, Sakai H, Takehara K, Honda S, Kanetake H. Analysis of numerical chromosomal aberrations in adrenal cortical neoplasms by fluorescence in situ hybridization. J. Urol. 2002; 168: 1370-73.
3. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 2000; 182: 311-22.
4. Wachenfeld C, Beuschlein F, Zwermann O et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur. J. Endocrinol. 2001; 145: 335-41.
5. Sasano H, Imatani A, Shizawa S, Suzuki T, Nagura H. Cell proliferation and apoptosis in normal and pathologic human adrenal. Mod. Pathol. 1995; 8: 111-17.
6. Goldblum JR, Shannon R, Kaldjian EP et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod. Pathol. 1993; 6: 663-8.
7. Wajchenberg BL, Albergaria Pereira MA, Medonca BB et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88: 711-36.
8. Yano T, Linehan M, Anglard P et al. Genetic changes in human adrenocortical carcinomas. J. Natl Cancer Inst. 1989; 81: 518-23.
9. Kjellman M, Kallioniemi OP, Karhu R et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res. 1996; 56: 4219-23.
10. Russell AJ, Sibbald J, Haak H, Keith WN, McNicol AM. Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage. Br. J. Cancer 1999; 81: 684-9.
11. Reincke M, Karl M, Travis WH et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab. 1994; 8: 790-94.
12. Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int. J. Cancer 1993; 54: 408-410.
13. Kanekawa A, Tsuji T, Oga A, Sasaki K, Shinozaki F. Chromosome 17 abnormalities in squamous cell carcinoma of the oral cavity, and its relationship with p53 and Bcl-2 expression. Anticancer Res. 1999; 19: 81-6.
14. Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J. Urol. 1978; 120: 660-65.
15. International Union Against Cancer. TNM Classification of Malignant Tumours, 5th edn. Wiley-Liss, New York, 1997.
16. Hopman AH, Ramaekers FC, Raap AK et al. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry 1988; 89: 307-16.
17. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 1984; 8: 163-9.
18. van Slooten H, Schaberg A, Smeenk D, Moolenaar AJ. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 1985; 55: 766-73.
19. Cibas ES, Medeiros LJ, Weinberg DS, Gelb AB, Weiss LM. Cellular DNA profiles of benign and malignant adrenocortical tumors. Am. J. Surg. Pathol. 1990; 14: 948-55.
20. Haak HR, Cornelisse CJ, Hermans J, Cobben L, Fleuren GJ. Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma. Br. J. Cancer 1993; 68: 151-5.
21. Gicquel C, Bertagna X, Gaston V et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001; 61: 6762-7.